港交所(00388.HK)续升3.5%曾逼近391元 传港股通扩至生物科技及第二上市股
市传施政报告将公布扩中港「互联互通」范围至生物科技及第二上市股。港交所(00388.HK)四连升,尤其是今天跑赢大市和大部分蓝筹,最高见390.8元,现造390元,续升3.5%,成交增至532万股,涉资20.55亿元。
特首林郑月娥与早前访京争取中央惠港措施,新一份施政报告因而延至明天(25日)公布。据《星岛日报》报道,中央支持的其中一项惠港金融措施,是扩大「互联互通」计划。据报实施六年的沪深港通机制,将扩大涵盖范围,内地投资者南下资金,将可买卖本港上市的生物科技股及第二上市股份,「北水」将可投资阿里巴巴(09988.HK)、京东(09618.HK)、网易(09999.HK)等重磅科技股。
此外,港交所公布开发沪深港通交易结算加速平台HKEX Synapse,进一步提高沪深港通交易结算效率。Synapse将利用DAML智能合约简化沪深港通北向交易的交易後工作流程,以透明、安全和可靠方式提高市场参与者的结算效率和结算能力,旨在帮助资产管理机构、证券经纪、全球及本地托管机构和结算参与者,更加高效地处理不断增长沪深港通交易量带来结算工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.